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Abstract
The frequency and severity of congenital malformations (CMF) do not tend to decline in modern society. CMF for etiologic
factors are referred to the pathologies of a multifactorial nature. Among the many causative factors of CMF there is a
hereditary predisposition.
The objective of the study was to increase the effectiveness of complex individualized prophylaxis of congenital malformations
in women with polymorphic alleles of genes of folate cycle enzymes, the second phase of the detoxification system through
the use of diagnostic, preventive, and therapeutic measures.
Materials and methods. 120 women of reproductive age who live in the city of Odessa and the Odessa region were
examined. The alleles of the genes of the folate cycle enzymes of methylenetetrahydrofolate reductase (MTHFR), 5-
methyltetrahydrofolate homocysteine methyltransferase reductase (MTRR), glutathione-S-transferase M1 (GSTM1), folate
acid, cyanocobalamin were determined.
Results. The determination of the polymorphic alleles of the genes of the folate cycle enzymes of methylenetetrahydrofolate
reductase (MTHFR), 5-methyltetrahydrofolate homocysteine methyltransferase reductase (MTRR), glutathione-S-transferase
M1 (GSTM1), low folate, cyanocobalamin indicates the presence of a hereditary predisposition to the emergence of CMF,
before and during pregnancy. Polymorphism of genes that control the synthesis of GSTM1 may alter the activity of
detoxification enzymes. Expression of genes of GSTM1 enzymes begins in the embryonic period. Glutathione-dependent
detoxification plays a key role in disinfecting of DNA peroxides. Mistakes of metabolism, functions of the corresponding
enzymes are realized by chromosomal abnormalities and the risk of the occurrence of CMF, which requires the use of
antioxidant therapy before and during pregnancy.
Conclusions. It was found that a high (about 55%) frequency of the polymorphic alleles of the genes of folate cycle enzymes
MTHFR (homozygous - 10.0%, heterozygous - 16.7%), 5 MTRR (homozygous 12.5%, heterozygous - 15.5%) , the second
phase of the GSTM1 detoxification system (homozygous - 13.3%, heterozygous - 15.8%), the content below the reference
values of folic acid in 26.7%, cyanocobalamin - in 63.4% of observations indicates a hereditary predisposition and may
contribute the emergence of CMF, which explains the expediency of timely use of preventive measures including folates,
antioxidants.
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Problem statement and analysis of the
recent research
Prevention of congenital malformations (CMF) is one of the
most urgent tasks of modern medicine and society as a whole.
The urgency of this problem lies in the high frequency of oc-
currence of CMF (stable morphological changes in the organ,
organs that arise as a result of disturbances in morphogenesis
in the antenatal period), congenital anomalies of development
(structural, functional, metabolic disorders of the organ, or-
gans that arise in utero) and their dissemination [1].
The emergence and formation of CMF is recognized as
a polyethiological process. The pathogenetic mechanism of
multifactorial pathology is complex and is constantly being
studied. At the heart of the formation of embryonic develop-
mental defects, the term gestation, the direct damaging factor,
the destruction of tissues, the dysentogenesis, etc. is impor-
tant. [6]. The formation of an organ in the embryonic period
is determined by the interaction of three main factors: 1) the
genetic mechanism; 2) internal epigenetic factors (enzyme
systems, hormones, etc.); 3) external epigenetic factors (the
influence of the external environment) [5]. The complexity
of isolating one primary isolated causative factor explains the
constant search for scientists in this direction.
It is generally recognized that metabolic processes, includ-
ing the folate cycle and the tricarboxylic acid cycle, occur with
the participation of vitamins, macro- and microelements under
the control of the corresponding genes. Folates, vitamins and
vitamin-like compounds of group ”B” are part of enzymes,
coenzymes [2, 4]. Deficiency of nicotinamide, flavoprotein
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dehydrogenases, ribonucleic acids leads to a disruption in the
synthesis of proteins, cellular enzymes, compounds such as
amino acids, carbohydrates, fatty acids, the energy source of
ATP (adenosine triphosphate), and complex metabolic shifts.
The folate cycle is a cascade process controlled by enzymes
that have folate derivatives as coenzymes. The key point in
this process is the synthesis of the amino acid methionine
with homocysteine. Violation of the folate cycle is dangerous
for embryonic cells, which quickly divide. Hyperhomocys-
teinemia leads to endothelial dysfunction, hypermethylation
of DNA, disruption of chromosome separation, contributes
to the emergence of CMF [3, 5]. The foregoing emphasizes
the relevance of the problem under study and explains the
appropriateness of an individual approach to preventing the
occurrence of CMF by correcting the content of folates, trace
elements, antioxidant vitamins, amino acids, and carrying out
individualized pre-conceptual preparation for future parents
from the perspective of predictive medicine.
The objective of the study was to increase the effectiveness
of complex individualized prophylaxis of congenital malfor-
mations in women with a deficiency of B vitamins, polymor-
phic alleles of folate cycle genes, and a phase II detoxification
system using diagnostic, prophylactic, therapeutic measures.
1. Materials and methods of the research
120 native women of Odessa and Odessa region aged from 18
to 35 years before and during pregnancy were examined, who
were on dispensary records in women’s consultations. In the
main group (I) and the comparison group (II), 60 subjects are
included, depending on the prescribed preventive, therapeutic
measures.
The level of folic acid, cyanocobalamin was determined
in the blood by the immunochemical method; alleles of the
677T gene of the enzyme methylenetetrahydrofolate reductase
(MTHFR), 5-methyltetrahydrofolate homocysteine methyl-
transferase reductase (MTRR), glutathione-S-transferase M1
(GSTM1) by polymerase chain reaction (PCR).
For the purpose of correcting the content of vitamins,
macro-, microelements, amino acids, stabilization of metabolic
processes, all subjects were assigned to use micronutrients in
daily doses (food containing natural folates (spinach, broccoli,
nuts, peanuts, hazelnuts, almonds, beans, Vitamin complexes
Femibion (Natalker) containing folic acid 400 µg and folic
acid acid 200 µg, calcium- (Metafolin-equivalent to 200 µg
folic acid), vitamins B1 (1.2 mg), B6 (1, 9 mg), B2 (1.6 mg),
B12 (3.5 mg), biotin (60 µg), iodine (150 µ), Vitamin C (110
mg), nicotinamide (15 mg), vitamin E (13 mg), pantothenic
acid (6 mg), docosahexanoic acid 200 mg) were administered
to women in the main group. Women of the comparison
group were prescribed drugs, regulated by Order No. 417 of
the Ministry of Health of Ukraine on 15.07.2011. The groups
of subjects did not include women with hyperthyroidism.
2. Results of the research and their
discussion
According to a retrospective analysis of medical records and
the results of a prospective examination, the incidence of ex-
tragenital pathology, gynecological diseases, and the obstetric
history data did not have a significant difference between the
groups.
Thus, out of 120 examined women in 63.3% had cardio-
vascular system diseases, 46.7% had thyroid pathology, 36.7%
had hepatopancreatobiliary system diseases, gastrointestinal
tract, including chronic constipation, 26.7% - diseases of the
urinary system.
13.3% of women suffered from iron deficiency anemia
before pregnancy. Birth in the history had 53.3%, medical
abortion - 30.0%, spontaneous abortion - 30.0% of the sur-
veyed. Violations of menstrual function noted 20.0%, primary
infertility - 6.7% of women.
Analysis of the results of laboratory studies showed that of
the 120 women in 26.7% of women, content of the folate acid
was lower than the reference values (<4.6 ng / ml), 17.0% at
the lower limit of the norm (5.0-7, 0 ng/ml). In 56.3% of the
subjects, the level of folic acid was determined at the upper
limit of the norm (17.0-19.0 ng/ml). In 36.6% of women the
level of cyanocobalamin was lower and at the lower limit of
the norm (180.0 - 200.0 pg/ml).
The result of the determination of the alleles of the genes
of the folate cycle enzymes showed that the MTHFR poly-
morphism over the T allele was detected in 32 (26.7%) cases:
homozygous - in 12 (10.0%), heterozygous - in 20 (16.7%);
MTRR - in 33 (27.5%): homozygous - in 15 (12.5%, heterozy-
gous - in 18 (15.0%, GST M1 - in 35 (29.2%): homozygous
in 16 (13, 3%, heterozygotes - in 19 (15.8%).
The combined deficiency of vitamins (folic acid, cyanocobal-
amin) was determined in 92 (76.7%) of the subjects. The
combined polymorphism of the genes of folate cycle enzymes
(MTHFR, MTRR) was in 65 (54.2%) pregnant women. The
combined polymorphism of the folate cycle enzyme genes
(MTHFR MTRR) and the II phase of the detoxification system
(GST M1) were in 00 (83.3%) women.
The presence of polymorphic alleles of the genes of folate
cycle enzymes (MTHFR, MTRR), the II phase of the detoxifi-
cation system (GST M1) was assessed as indications for the
administration of a complex of vitamins containing directly
folate, a microelement of iodine, antioxidant vitamins C, E,
docosahexaenoic acid. The presence of polymorphic alleles
of the folate cycle genes indicates that synthetic folic acid
cannot be absorbed in the body, since corresponding enzymes
are necessary for its metabolism, including 5 methyltetrahy-
drofolate. The only form of vitamin B9 - L-methylfolate has
biological activity and is able to participate in the synthesis of
DNA, cell replication, methylation.
In the dynamics of monitoring the course of pregnancy, a
comparative analysis between the observation groups showed
that the decrease in the content of the studied vitamins in
the 18-20 and 36-37 weeks of pregnancy was significantly
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lower in 28 (46.6%) women who received traditional treat-
ment against 5 (8.3 %) of the group of women who received
the drug containing vitamin complex. Individualized approach
to the correction of the content of vitamins, macro-, microele-
ments, amino acids by the laboratory (PCR) assessment of
the hereditary disruption of enzyme activity to determine the
presence of polymorphism (homozygous, heterozygous) and
the combined alleles of the folate cycle genes, the II phase of
the detoxification system had a positive value of 57 95.0%)
of the subjects, which confirms its effectiveness. The offered
nutrient and drug therapy helped stabilize the indices that
were determined: the content of folic acid, cyanocobalamin,
homocysteine, coagulogram, liver tests, general blood and
urine analysis, total protein.
The obtained results of laboratory studies were coordi-
nated with the clinical evaluation of the condition of women,
the feto-placental complex by trimester of gestation, which
significantly confirms the positive value of the individualized
pathogenetically grounded approach to the prevention of CMF
and gestational complications.
Proposed individualized prophylaxis of CMF includes
four stages: I stage-examination; II stage - preparatory; III
stage - planning of pregnancy; IV stage - prenatal diagnosis.
Important is the laboratory evaluation of the metabolism of
connective tissue, the content of vitamins and vitamin-like
compounds of group ”B”, homocysteine, expression of genes
of folate cycle enzymes (MTHFR, MTRR), and the second
phase of the detoxification system (GSTm1).
CMF were not diagnosed in fetuses and newborns in the
women surveyed. The proposed therapy contributed to a
significant decrease the frequency of the threat of termination
of pregnancy in 3.1 times, the threat of premature births - in
3.2 times, placental dysfunction - in 3.5 times, fetal growth
retardation syndrome - in 3.0 times, gestational anemia - in 4.1
time, gestational pyelonephritis - in 3.2 times, pre-eclampsia -
in 2.5 times (p <0.001) with respect to the comparison group.
3. Conclusions
Prevention of CMF is one of the priorities of physicians of all
specialties. It is the prevention of the emergence and forma-
tion of embryonic developmental defects that can contribute
to the prevention of this pathology. There are no causeless
malformations; there is unqualified or late diagnosis of these
conditions and untimely preventive measures.
It is advisable to begin prophylaxis of CMF not earlier
than 3 - 4 months before fertilization. This makes it possi-
ble to evaluate the pre-morbid background of the organisms
of future parents, to determine and conduct a pathogeneti-
cally substantiated differentiated, individualized, complex,
stage, full-fledged correction of metabolic disorders, taking
into account the hereditary disruption of the activity of the
corresponding enzymes.
About 55% of Russian women are carriers of polymorphic
alleles of genes of folate cycle enzymes (MTHFR: homozy-
gous - 10.0%, heterozygous - 16.7%), MTRR: homozygous
- 12.5%, heterozygous - 15.5%), II phase Detoxification sys-
tems (GST M1: homozygous - 13.3%, heterozygous - 15.8%).
The combined polymorphism was 83.3%.
Given the high frequency of the genome polymorphism
of the folate cycle enzymes (MTHFR, MTRR), the II phase
of the detoxification system (GST M1), the combined poly-
morphism, a pathogenetically substantiated indication is the
direct administration of folates. Preparations of choice for the
correction of the content of vitamins, macro-, microelements,
aminoacids is the vitamin complex Femibion.
4. Prospects for research
Prospects for research in this area will be further develop-
ment of the use of folates for the prevention of congenital
malformations.
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